Comparison of two methods of administration of deferoxamine (intravenous and subcutaneous) in terms of impact on reducing iron overload in thalassemia patients who have suffered heart failure.
Phase 2
- Conditions
- Iron overload..Abnormal level of blood mineral.
- Registration Number
- IRCT201206289827N2
- Lead Sponsor
- Kermanshah University of Medical Sciences and Health Services
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete
- Sex
- All
- Target Recruitment
- 42
Inclusion Criteria
suffering major Thalassemia and cardiac ejection fraction less than 50%.
Exclusion criteria: inflammatory disease; anemia and liver disorders.
Exclusion Criteria
Not provided
Study & Design
- Study Type
- interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Serum ferritin. Timepoint: 1 week after intervention (desferal administration). Method of measurement: Use of ELISA method, unit will be mg/L.
- Secondary Outcome Measures
Name Time Method Cardiac Ejection Fraction. Timepoint: 2 weeks after intervention. Method of measurement: Using Ecocardiography, the unit will be percent.
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What molecular mechanisms underlie deferoxamine's efficacy in reducing cardiac iron overload in thalassemia major patients with heart failure?
How does high-dose intravenous deferoxamine compare to subcutaneous administration in managing iron-induced cardiomyopathy in thalassemia major?
Which biomarkers correlate with improved ejection fraction following deferoxamine therapy in iron-overloaded thalassemia patients?
What are the adverse event profiles of high-dose intravenous versus subcutaneous deferoxamine in thalassemia major patients with cardiac dysfunction?
How do deferoxamine's chelation mechanisms compare to other iron overload treatments like deferiprone or deferasirox in thalassemia-induced cardiomyopathy?